Stimulation of β-catenin and colon cancer cell growth by the KDM4B histone demethylase

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1341-1348

  Berry, William L ^a   Kim, Tae Dong ^a   Janknecht, Ralf ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

catenin; Colon cancer; Gene transcription; Histone; KDM4B

Indexed keywords

BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; BETA CATENIN; CCND1 PROTEIN, HUMAN; CYCLIN D1; DNA BINDING PROTEIN; HISTONE DEMETHYLASE; KDM4B PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MYC PROTEIN; MYC PROTEIN, HUMAN; SMALL INTERFERING RNA; TCF4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

BIOSYNTHESIS; CELL PROLIFERATION; CELL TRANSFORMATION; COLON TUMOR; GENETIC TRANSCRIPTION; GENETICS; HT 29 CELL LINE; HUMAN; METABOLISM; PATHOLOGY; PROMOTER REGION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; CYCLIN D1; DNA-BINDING PROTEINS; HT29 CELLS; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MAP KINASE KINASE 4; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84894451091     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2279     Document Type: Article

References (61)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480, 2006.
3. Chi P, Allis CD and Wang GG: Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 10: 457-469, 2010.
4. Kulis M and Esteller M: DNA methylation and cancer. Adv Genet 70: 27-56, 2010.
5. Dawson MA and Kouzarides T: Cancer epigenetics: from mechanism to therapy. Cell 150: 12-27, 2012.
6. Black JC, Van Rechem C and Whetstine JR: Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell 48: 491-507, 2012.
7. Kooistra SM and Helin K: Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 13: 297-311, 2012.
8. Berry WL and Janknecht R: KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res 73: 2936-2942, 2013.
9. Whetstine JR, Nottke A, Lan F, Huarte M, Smolikov S, Chen Z, Spooner E, Li E, Zhang G, Colaiacovo M and Shi Y: Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 125: 467-481, 2006.
10. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH and Helin K: The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 442: 307-311, 2006. (Pubitemid 44114906)
11. Klose RJ, Yamane K, Bae Y, Zhang D, Erdjument-Bromage H, Tempst P, Wong J and Zhang Y: The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature 442: 312-316, 2006. (Pubitemid 44114907)
12. Fodor BD, Kubicek S, Yonezawa M, O'Sullivan RJ, Sengupta R, Perez-Burgos L, Opravil S, Mechtler K, Schotta G and JenuweinT: Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes Dev 20: 13.
13. Shin S and Janknecht R: Diversity within the JMJD2 histone demethylase family. Biochem Biophys Res Commun 353: 973-977, 2007.
14. Trojer P, Zhang J, Yonezawa M, Schmidt A, Zheng H, Jenuwein T and Reinberg D: Dynamic histone H1 isotype 4 methylation and demethylation by histone lysine methyltransferase G9a/KMT1C and the Jumonji domain-containing JMJD2/KDM4 proteins. J Biol Chem 284: 8395-8405, 2009.
15. Weiss T, Hergeth S, Zeissler U, Izzo A, Tropberger P, Zee BM, Dundr M, Garcia BA, Daujat S and Schneider R: Histone H1 variant-specific lysine methylation by G9a/KMT1C and Glp1/KMT1D. Epigenetics Chromatin 3: 7, 2010.
16. Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP and Yang ZQ: Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 28: 4491-4500, 2009.
17. Yang J, Jubb AM, Pike L, Buffa FM, Turley H, Baban D, Leek R, Gatter KC, Ragoussis J and Harris AL: The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res 70: 6456-6466, 2010.
18. Kawazu M, Saso K, Tong KI, McQuire T, Goto K, Son DO, Wakeham A, Miyagishi M, Mak TW and Okada H: Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development. PLoS One 6: e17830, 2011.
19. Shi L, Sun L, Li Q, Liang J, Yu W, Yi X, Yang X, Li Y, Han X, Zhang Y, Xuan C, Yao Z and Shang Y: Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci USA 108: 7541-7546, 2011.
20. Berry WL, Shin S, Lightfoot SA and Janknecht R: Oncogenic features of the JMJD2A histone demethylase in breast cancer. Int J Oncol 41: 1701-1706, 2012.
21. Gaughan L, Stockley J, Coffey K, O'Neill D, Jones DL, Wade M, Wright J, Moore M, Tse S, Rogerson L and Robson CN: KDM4B is a master regulator of the estrogen receptor signalling cascade. Nucleic Acids Res 41: 6892-6904, 2013.
22. Wissmann M, Yin N, Muller JM, Greschik H, Fodor BD, Jenuwein T, Vogler C, Schneider R, Gunther T, Buettner R, Metzger E and Schule R: Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 9: 347-353, 2007.
23. Shin S and Janknecht R: Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem Biophys Res Commun 359: 742-746, 2007. (Pubitemid 46901127)
24. Coffey K, Rogerson L, Ryan-Munden C, Alkharaif D, Stockley J, Heer R, Sahadevan K, O'Neill D, Jones D, Darby S, Staller P, Mantilla A, Gaughan L and Robson CN: The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover. Nucleic Acids Res 41: 4433-4446, 2013.
25. Pollard PJ, Loenarz C, Mole DR, McDonough MA, Gleadle JM, Schofield CJ and Ratcliffe PJ: Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. Biochem J 416: 387-394, 2008.
26. Beyer S, Kristensen MM, Jensen KS, Johansen JV and Staller P: The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem 283: 36542-36552, 2008.
27. Kim TD, Oh S, Shin S and Janknecht R: Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D. PLoS One 7: e34618, 2012.
28. Oh S, Shin S, Lightfoot SA and Janknecht R: 14-3-3 proteins modulate the ETS transcription factor ETV1 in prostate cancer. Cancer Res 73: 5110-5119, 2013.
29. Mooney SM, Grande JP, Salisbury JL and Janknecht R: Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential. Biochemistry 49: 1-10, 2010.
30. Janknecht R: Regulation of the ER81 transcription factor and its coactivators by mitogen- and stress-activated protein kinase 1 (MSK1). Oncogene 22: 746-755, 2003.
31. Dowdy SC, Mariani A and Janknecht R: HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81. J Biol Chem 278: 44377-44384, 2003. (Pubitemid 37377186)
32. Goel A and Janknecht R: Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem 279: 14909-14916, 2004. (Pubitemid 38618881)
33. Papoutsopoulou S and Janknecht R: Phosphorylation of ETS transcription factor ER81 in a complex with its coactivators CREB-binding protein and p300. Mol Cell Biol 20: 7300-7310, 2000.
34. Knebel J, De Haro L and Janknecht R: Repression of transcription by TSGA/Jmjd1a, a novel interaction partner of the ETS protein ER71. J Cell Biochem 99: 319-329, 2006. (Pubitemid 44297974)
35. Wu J and Janknecht R: Regulation of the ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1 and protein kinase A. J Biol Chem 277: 42669-42679, 2002. (Pubitemid 35285636)
36. Rossow KL and Janknecht R: The Ewing's sarcoma gene product functions as a transcriptional activator. Cancer Res 61: 2690-2695, 2001. (Pubitemid 32685856)
37. Mooney SM, Goel A, D'Assoro AB, Salisbury JL and JanknechtR: Pleiotropic effects of p300-mediated acetylation on p68 and p72 RNA helicase. J Biol Chem 285: 30443-30452, 2010.
38. Goel A and Janknecht R: Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu. Mol Cell Biol 23: 6243-6254, 2003. (Pubitemid 37013101)
39. Oh S and Janknecht R: Histone demethylase JMJD5 is essential for embryonic development. Biochem Biophys Res Commun 420: 61-65, 2012.
40. Shin S, Oh S, An S and Janknecht R: ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells. Oncol Rep 29: 306-314, 2013.
41. DiTacchio L, Bowles J, Shin S, Lim DS, Koopman P and Janknecht R: Transcription factors ER71/ETV2 and SOX9 participate in a positive feedback loop in fetal and adult mouse testis. J Biol Chem 287: 23657-23666, 2012.
42. Shin S, Kim TD, Jin F, van Deursen JM, Dehm SM, Tindall DJ, Grande JP, Munz JM, Vasmatzis G and Janknecht R: Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res 69: 8102-8110, 2009.
43. Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ, Freudenberg J, Chen X, Haigis K, Jegga AG, Kong S, Sakthivel B, Xu H, Reichling T, Azhar M, Boivin GP, RobertsRB, Bissahoyo AC, Gonzales F, Bloom GC, Eschrich S, Carter SL, Aronow JE, Kleimeyer J, Kleimeyer M, RamaswamyV, Settle SH, Boone B, Levy S, Graff JM, Doetschman T, Groden J, DoveWF, Threadgill DW, Yeatman TJ, Coffey RJ Jr and Aronow BJ: Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 8: R131, 2007.
44. Kurashina K, Yamashita Y, Ueno T, Koinuma K, Ohashi J, HorieH, Miyakura Y, Hamada T, Haruta H, Hatanaka H, Soda M, Choi YL, Takada S, Yasuda Y, Nagai H and Mano H: Chromosome copy number analysis in screening for prognosis-related genomic regions in colorectal carcinoma. Cancer Sci 99: 1835-1840, 2008.
45. Clevers H and Nusse R: Wnt/beta-catenin signaling and disease. Cell 149: 1192-1205, 2012.
46. Yap KL and Zhou MM: Keeping it in the family: diverse histone recognition by conserved structural folds. Crit Rev Biochem Mol Biol 45: 488-505, 2010.
47. Mosimann C, Hausmann G and Basler K: Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol 10: 276-286, 2009.
48. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512, 1998. (Pubitemid 28425575)
49. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ and Hanski C: Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 96: 1603-1608, 1999. (Pubitemid 29098498)
50. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R and Ben-Ze'ev A: The Cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96: 5522-5527, 1999. (Pubitemid 29234650)
51. Tetsu O and McCormick F: Beta-catenin regulates expression of Cyclin D1 in colon carcinoma cells. Nature 398: 422-426, 1999. (Pubitemid 29180374)
52. Kouzarides T: Chromatin modifications and their function. Cell 128: 693-705, 2007.
53. Daujat S, Zeissler U, Waldmann T, Happel N and Schneider R: HP1 binds specifically to Lys26-methylated histone H1.4, whereas simultaneous Ser27 phosphorylation blocks HP1 binding. J Biol Chem 280: 38090-38095, 2005.
54. Wagner EJ and Carpenter PB: Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol 13: 115-126, 2012.
55. Eilers M and Eisenman RN: Myc's broad reach. Genes Dev 22: 2755-2766, 2008.
56. Eferl R and Wagner EF: AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868, 2003. (Pubitemid 37383716)
57. Smith DR, Myint T and Goh HS: Over-expression of the c-myc proto-oncogene in colorectal carcinoma. Br J Cancer 68: 407-413, 1993. (Pubitemid 23229447)
58. Magrisso IJ, Richmond RE, Carter JH, Pross CB, GilfillenRA and Carter HW: Immunohistochemical detection of RAS, JUN, FOS, and p53 oncoprotein expression in human colorectal adenomas and carcinomas. Lab Invest 69: 674-681, 1993. (Pubitemid 24026848)
59. Nateri AS, Spencer-Dene B and Behrens A: Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 437: 281-285, 2005. (Pubitemid 41294493)
60. Gan XQ, Wang JY, Xi Y, Wu ZL, Li YP and Li L: Nuclear Dvl, c-Jun, beta-catenin, and TCF form a complex leading to stabilization of beta-catenin-TCF interaction. J Cell Biol 180: 1087-1100, 2008. (Pubitemid 351468467)
61. Suto R, Tominaga K, Mizuguchi H, Sasaki E, Higuchi K, Kim S, Iwao H and Arakawa T: Dominant-negative mutant of c-Jun gene transfer: a novel therapeutic strategy for colorectal cancer. Gene Ther 11: 187-193, 2004. (Pubitemid 38159691)